The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $3.57 in the prior trading day, Prime Medicine Inc (NASDAQ: PRME) closed at $3.5, down -1.96%. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 2.35 million shares were traded. PRME stock price reached its highest trading level at $3.7 during the session, while it also had its lowest trading level at $3.5.
Ratios:
Our goal is to gain a better understanding of PRME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.56 and its Current Ratio is at 3.56. In the meantime, Its Debt-to-Equity ratio is 1.97 whereas as Long-Term Debt/Eq ratio is at 1.85.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when GV 2021 GP, L.L.C. bought 1,500,000 shares for $3.30 per share. The transaction valued at 4,950,000 led to the insider holds 3,262,440 shares of the business.
NELSEN ROBERT bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The Director now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners XII, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 623958976 and an Enterprise Value of 476841088. For the stock, the TTM Price-to-Sale (P/S) ratio is 125.74 while its Price-to-Book (P/B) ratio in mrq is 7.73. Its current Enterprise Value per Revenue stands at 96.118 whereas that against EBITDA is -2.416.
Stock Price History:
The Beta on a monthly basis for PRME is 2.41, which has changed by -0.19908464 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $5.17, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 5.23%, while the 200-Day Moving Average is calculated to be 31.66%.
Shares Statistics:
The stock has traded on average 4.28M shares per day over the past 3-months and 3935850 shares per day over the last 10 days, according to various share statistics. A total of 134.49M shares are outstanding, with a floating share count of 94.42M. Insiders hold about 47.24% of the company’s shares, while institutions hold 22.11% stake in the company. Shares short for PRME as of 1753920000 were 21851787 with a Short Ratio of 5.11, compared to 1751241600 on 20144917. Therefore, it implies a Short% of Shares Outstanding of 21851787 and a Short% of Float of 33.76.
Earnings Estimates
The stock of Prime Medicine Inc (PRME) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.11 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.06 and -$1.45 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$0.87, with 10.0 analysts recommending between -$0.56 and -$1.51.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $36.12M, while the lowest revenue estimate was $2.57M, resulting in an average revenue estimate of $11.23M. In the same quarter a year ago, actual revenue was $2.98M
